



Docket No. PRD2122USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dominique Mabire

Serial No.: 10/596,083

Art Unit:

Filed

: November 18, 2004

Examiner:

For

: SUBSTITUTED 6-CYCLOHEXYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY (ADP-RIBOSE) POLYMERASE INHIBITORS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 30, 2006
(Date of Deposit)

Alana G. Kriegsman
(Name of applicant, assignee, or Registered Representative)

/Alana G. Kriegsman/

(Signature)

October 30, 2006

(Date of Signature)

Mail Stop: Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

•

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☑ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In a	ccordance with §1.129(a), this Information
Disclosure Stat	ement is being filed in connection with \square the
first or 🗌 seco	nd After Final Submission, therefore:
	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

_	ttached); or
☐ Ple	ease charge Deposit Account No. 10- 50/ / the fee of \$180.00 as set forth
Disclosure Statement either a Final Actunder §1.311 but Applicant(s) herek Information Disclosure with §1 \$180.00 as set for Copies of C	of each of the references listed on the
Copies o	of references listed on the attached Form PTO herewith EXCEPT THAT:
[li	view of the voluminous nature of references ist as appropriate], and the likelihood that ese references are available to the Examiner, pies are not enclosed herewith.
ava end	any of the foregoing publications are not ailable to the Examiner, Applicant will deavor to supply copies at the Examiner's quest.
	of only foreign patent documents and non- are enclosed in accordance with 37 CFR 1.98

oxtimes There are no listed refere	ences which are not in the
English language.	
The relevance of those lis	sted references which are
not in the English language is as fo	ollows:
igtigthedown Attached are copies of sea	arch report(s) from
corresponding patent application(s),	, which are listed on the
attached Submission Under MPEP 609 I).
Attached are the following	g non-published pending
patent applications which may be dee	emed relevant, which are
listed on the attached Submission Ur	nder MPEP 609 D.
Please charge any deficiency or	r credit any overpayment to
Deposit Account No. 10-0750/PRD2122U	JSPCT/AGK. This form is
submitted in triplicate.	
Respe	ctfully submitted,
/Alan	a G. Kriegsman/
Alana	G. Kriegsman
	No. 41,747 ney for Applicants
ACCOL	ney for Applicance
Johnson & Johnson	

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1495 DATED: October 30, 2006



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

collection of information unless it displays a valid OMB control number.					
Application Number	10/596,083				
Filing Date	11/18/2004				
First Named Inventor	Dominique Mabire				
Group Art Unit					
Examiner Name					
Attorney Docket Number	PRD2122USPCT				

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² Examiner Cite where relevant passages or relevant figures appear of Cited Document of Cited Document Initials (if known) Number mm-dd-yyyy 5177075 Warner-Lambert Company 01-05-1993

FOREIGN PATENT DOCUMENTS

		Foreign Patent Do	Patent Docume	ument	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner City Initials No.		Office ³	Number⁴ K	indCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		EP	0371564	B1	Janssen Pharmaceutica, N.v.	06-06-1990		

Examiner		Date		
		2000		
Signature I		Considered		
o.gata.o		 1 001.0100100	<u> </u>	
	 	 	44 1 1 1 1 1	

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a concentration unionitation unless it displays a	Valid Civid Control Humber.
Application Number	10/596,083
Filing Date	11/18/2004
First Named Inventor	Dominique Mabire
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD2122 USPCT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*				
		LI et al., "PARP Inhibitors", <u>IDrugs</u> , 2001, pages 804-812, Vol. 4, No. 7, Current Drugs Ltd., GB.		
		WELTIN et al., "Effect of 6(5-Phenanthridinone, an Inhibitor of Poly(ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncology Research, 1994, pages 399-403, Vo.l. 6, No. 9, Elsevier Science Ltd., USA.		
	l			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



Examiner Signature

SUBMISSION UNDER MPEP 609 D

Application Number 10/596,083

Filing Date 11/18/2004

First Named Inventor Dominique Mabire

Group Art Unit

Examiner Name

Attorney Docket Number PRD2122USPCT

Page 1 of 1

U.S. PATENT DOCUMENTS

			U.S. Patent Docu	U.S. Patent Document			
Examiner Initials			Number		nd Code ² known)	Pages, Columi where relevant p relevant figure	assages or
						*	
				-	 		
					-		
					ļ		
			·				
						-	
					ļ		
					7, 31		
		FOREIGN	PATENT DOCUME	NTS			
			Foreign Patent Docur	ment		Columns, Lines,	
Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Office ³ Number ⁴	KindCode ⁵	where relevant passages or relevant figures appear		T ⁶
				l			
					1		
						<u> </u>	
		OTHER PRIOR ART - NO	N PATENT LITERATU	URE DOCUMEN	ITS		<u> </u>
Examiner 's Initials*	Cite No.1	Include name of the author (in CA title of the item (book, magazine, volume-issue number(s)	APITOL LETTERS), journal, serial, symp	title of the articosium, catalo	cle (when a, etc.), d	ate, page(s).	T²
		PCT Intl. Search Report, PCT/EP2004/0	13165,March 24, 2005				
					. <u>-</u>		
						- 10	

Date Considered